3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
2
Withdrawn
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Mycosis Fungoides
3
Multiple Myeloma
3
Neoplasms, Plasma Cell
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, T-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell
2
Burkitt Lymphoma
2
Uveal Melanoma
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sezary Syndrome
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Mesothelioma, Malignant
1
Mesothelioma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Advanced Cancers
1
Interventions
Peripheral Blood Stem Cell Transplantation
2
Melphalan
2
Etoposide
2
Cytarabine
2
Cyclophosphamide
2
Carmustine
2
tenalisib
1
tazemetostat
1
romidepsin
1
fludarabine phosphate
1
etoposide phosphate
1
Whole-Body Irradiation
1
Vorinostat
1
Vincristine
1
Transplantation
1
Tacrolimus
1
Prednisone
1
Prednisolone
1
O(6)-benzylguanine
1
Mycophenolic Acid
1
IMC-001
1
E7777 fusion protein
1
Doxorubicin
1
Cord Blood Stem Cell Transplantation
1
Bortezomib
1
4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide
1
10-propargyl-10-deazaaminopterin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Lymphoma, T-Cell, Peripheral
×
Vorinostat
×
Clear all
NCT00837174
2017-09-19
COMBOSTAT
The Methodist Hospital Research Institute
Phase 2
Withdrawn